Home/ Stocks/ CABA

Cabaletta Bio, Inc. Common Stock

CABA XNAS

$2.79 +0.06 (+2.04%) ▲ 15-min delayed

Open

$2.80

High

$2.82

Low

$2.74

Volume

2.70M

Market Cap

$450.03M

About Cabaletta Bio, Inc. Common Stock

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 158 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-43,515,000	$-0.39
FY 2025	$0	$-167,856,000	$-2.10
Q3 2025	$0	$-44,866,000	$-0.44
Q2 2025	$0	$-45,128,000	$-0.73

Related Market News

No specific coverage for CABA yet. Check out our latest market news or earnings calendar.

Get CABA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cabaletta Bio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.